Celldex Therapeutics reported $459.22M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Agenus USD 95.28M 38.15M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Celldex Therapeutics USD 459.22M 75.44M Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Northwest Biotherapeutics USD 7.2M 1.04M Sep/2025
Pfizer USD 42.82B 76M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025